$30.04
1.73% today
Nasdaq, Nov 20, 10:00 pm CET
ISIN
US3723032062
Symbol
GMAB

Genmab - ADR Stock price

$30.57
+0.03 0.10% 1M
+10.39 51.49% 6M
+9.70 46.48% YTD
+10.07 49.12% 1Y
-12.87 29.63% 3Y
-5.56 15.39% 5Y
+18.43 151.85% 10Y
+26.80 710.45% 20Y
Nasdaq, Closing price Wed, Nov 19 2025
+0.25 0.82%
ISIN
US3723032062
Symbol
GMAB
Industry

New AI Insights on Genmab - ADR Insights AI Insights on Genmab - ADR

How does the company make money?
Who are the company’s main competitors?
What are the key opportunities and risks?

Key metrics

Basic
Market capitalization
$18.2b
Enterprise Value
$17.7b
Net debt
positive
Cash
$527.0m
Shares outstanding
61.6m
Valuation (TTM | estimate)
P/E
8.3 | 11.4
P/S
32.9 | 31.6
EV/Sales
32.0 | 30.7
EV/FCF
95.3
P/B
20.5
Financial Health
Equity Ratio
80.1%
Return on Equity
22.3%
ROCE
21.0%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$553.5m | $576.7m
EBITDA
$214.2m | $213.5m
EBIT
$204.0m | $192.0m
Net Income
$228.9m | $164.9m
Free Cash Flow
$186.0m
Growth (TTM | estimate)
Revenue
24.7% | 19.6%
EBITDA
42.3% | 28.9%
EBIT
41.8% | 21.1%
Net Income
119.8% | -6.2%
Free Cash Flow
26.2%
Margin (TTM | estimate)
Gross
94.3%
EBITDA
38.7% | 37.0%
EBIT
36.9%
Net
41.4% | 28.6%
Free Cash Flow
33.6%
More
EPS
$3.7
FCF per Share
$3.0
Short interest
1.7%
Employees
3k
Rev per Employee
$180.0k
Show more

Is Genmab - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,048 stocks worldwide.

Genmab - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

26 Analysts have issued a Genmab - ADR forecast:

18x Buy
69%
6x Hold
23%
2x Sell
8%

Analyst Opinions

26 Analysts have issued a Genmab - ADR forecast:

Buy
69%
Hold
23%
Sell
8%

Financial data from Genmab - ADR

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
554 554
25% 25%
100%
- Direct Costs 32 32
82% 82%
6%
522 522
22% 22%
94%
- Selling and Administrative Expenses 92 92
16% 16%
17%
- Research and Development Expense 226 226
11% 11%
41%
214 214
42% 42%
39%
- Depreciation and Amortization 10 10
53% 53%
2%
EBIT (Operating Income) EBIT 204 204
42% 42%
37%
Net Profit 229 229
120% 120%
41%

In millions USD.

Don't miss a Thing! We will send you all news about Genmab - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Genmab - ADR Stock News

Neutral
GlobeNewsWire
about 2 hours ago
Company Announcement COPENHAGEN, Denmark; November 20, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 6,933 restricted stock units and 7,377 warrants to employees of the Company and the Company's subsidiaries. Each restricted stock unit is awarded cost-free and provides the owner with a conditional right to receive one share in Genmab A/S of nomina...
Neutral
GlobeNewsWire
one day ago
Company Announcement COPENHAGEN, Denmark; November 19, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons.
Neutral
GlobeNewsWire
2 days ago
Media Release COPENHAGEN, Denmark; November 18, 2025 Genmab A/S (Nasdaq: GMAB) (“Genmab”) announced today that it and its wholly owned subsidiary Genmab Finance LLC (“Genmab Finance”) have priced their previously announced offering of $1.5 billion of 6.250% senior secured notes due 2032 (the “Secured Notes”) and $1.0 billion of 7.250% senior unsecured notes due 2033 (the “Unsecured Notes,” and ...
More Genmab - ADR News

Company Profile

Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel in 1999 and is headquartered in Copenhagen, Denmark.

Head office Denmark
CEO Jan Winkel
Employees 2,682
Founded 1998
Website www.genmab.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today